<p><em>这家医疗数据和工具提供商有望突破盈亏平衡点，得益于人工智能的普及，但持续盈利的前景仍不确定</em></p>
<p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1024" height="760" original-src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg"/></p>
<p><em><strong>图片来源：Bamboo Works</strong></em></p>
<h4><strong>关键要点：</strong></h4>
<ul>
<li>公司表示预计截至 3 月底的财年将实现净利润约为 600 万至 800 万美元</li>
<li>医渡科技的人工智能工具正在被纳入医疗工作流程，一些客户医院的使用频率接近每天 1000 次</li>
</ul>
<p>多年来，医疗人工智能引发了大量的兴奋，但一直难以证明其盈利能力。这种情况可能正在发生变化，因为一家中国医疗科技提供商准备迎来盈利里程碑。</p>
<p><strong>医渡科技有限公司</strong>（2158.HK）<strong>宣布</strong> 于 4 月 20 日预计将在其 11 年历史中首次实现年度盈利，这可能标志着更广泛的人工智能驱动医疗行业的转折点。</p>
<p>这家为医疗行业提供大数据和技术解决方案的供应商预计截至 3 月底的财年将实现净利润在 4100 万至 5600 万元人民币（600 万至 820 万美元）之间，较去年约 1.18 亿元的亏损有所回升。</p>
<p>在解释扭转局面时，公司提到新订单激增，因为它将人工智能整合到其产品中，从而推动了更高的毛利率，以及更好的运营效率和规模经济。</p>
<p>从医渡科技的半年财报中可以清楚地看出，该公司正朝着盈亏平衡的方向发展。截止 9 月底的六个月收入增长了 8.7%，达到 3.58 亿元，扭转了去年同期的收缩。毛利率从 35.6% 上升至 37.4%。运营亏损缩小了 71%，降至 1571 万元，净亏损缩小了 72%，降至 1576 万元。</p>
<p>这些中期结果显示，增长越来越多地由医院的应用解决方案和支付系统驱动，而不是制药服务。</p>
<p>公司大数据平台和解决方案的半年收入同比增长 14.6%，而健康管理部门的收入跃升 30.3%。相比之下，针对制药公司的生命科学解决方案下降了 4.4%。在收入构成方面，大数据平台业务仍然是收入的最大贡献者。</p>
<p>随着人工智能的势头从大型模型转向实际部署，投资者越来越关注该技术是否能够嵌入工作流程以产生回报。在医疗保健领域，这意味着将人工智能整合到临床护理、研究或支付系统中。</p>
<p>迄今为止，只有少数中国人工智能医疗公司跨越了盈利门槛。例如，<strong>科大讯飞医疗</strong>（2506.HK）专注于初级护理和语音交互场景。它通过标准化工具迅速扩展，但在 2025 年仍报告亏损 6479 万元。<strong>Airdoc 科技</strong>（2251.HK）专注于单点应用，如视网膜图像识别，商业模式相对清晰但有限，去年亏损 2497 万元。</p>
<p>医渡科技采取了不同的路径。在早期阶段，公司开发了医疗平台和特定疾病数据库，建立了大量结构化数据和广泛的医院客户基础。最近，它已从单纯提供信息转变为通过临床助手和基于证据的人工智能代理参与医疗决策。</p>
<p>根据半年财报中的使用数据，这些工具似乎正在逐渐融入临床工作流程，一些医院的访问频率接近每天 1000 次。这种高频率的使用可能是从人工智能驱动的医疗业务中产生稳定回报的关键。</p>
<p>与此同时，公司在服务超过 1 万家医疗机构和与 100 多家顶级医院合作方面展示了可扩展性。然而，广泛采用与经济回报之间的相关性尚未明确建立。</p>
<h4><strong>前景不确定</strong></h4>
<p>收入增长仍处于个位数，没有明显加速的迹象。根据全年初步数据，很难判断利润的可持续性。此外，医疗人工智能的采用高度依赖于医院采购周期和政府支持政策，影响扩展的速度和范围。</p>
<p>公司仍可能处于过渡阶段，其商业模式正在形成但尚未得到验证。医渡科技的盈利突破表明，人工智能医疗在特定场景中可以实现货币化，但可能无法在整个行业中持续或复制。</p>
<p>尽管如此，利润预测推动了公司股价的上涨。在公告后，股价上涨 3.8%，收于 6.3 港元，年初至今涨幅为 18.4%。医渡科技的市销率约为 7.5 倍，基本与科大讯飞医疗的约 8 倍和 Airdoc 科技的约 6 倍相当。这表明投资者仍然基于收入规模和增长潜力而非盈利能力来评估其价值。</p>
<p>如果医渡科技在接下来的几个季度内能够保持盈利并加速收入增长，股价可能还有上涨空间。但如果利润下滑，估值可能已经达到顶峰。</p>
<p><em>要订阅 Bamboo Works 每周的免费通讯，请点击</em> 这里</p>
<p><strong><em>Benzinga 免责声明：本文来自未付的外部贡献者。它不代表 Benzinga 的报道，并且未经过内容或准确性的编辑。</em></strong></p>

医渡科技

<p>医渡科技预计将在截至三月的财年中实现首个年度盈利，预计净利润为 600 万至 800 万美元，这标志着医疗保健领域人工智能的潜在转折点。该公司在医疗工作流程中看到其人工智能工具的采用率增加，一些医院每天使用这些工具近 1000 次。尽管如此，由于收入增长缓慢和对医院采购周期的依赖，持续盈利的前景仍然不确定。在公告发布后，医渡科技的股价上涨了 3.8%</p>

<p><em>The provider of healthcare data and tools is poised to pass the breakeven point, helped by rising AI uptake, but the outlook for sustained profits remains uncertain</em></p>
<div class="lb-trans"><p><em>这家医疗数据和工具提供商有望突破盈亏平衡点，得益于人工智能的普及，但持续盈利的前景仍不确定</em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg" alt="" original-src="https://contributor-assets.benzinga.com/wp-content/uploads/2026/04/24023316/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_24-4-2026_103143_thebambooworks.com_-1024x760.jpeg"/></p>
<p><em><strong>image credit: Bamboo Works</strong></em></p>
<div class="lb-trans"><p><em><strong>图片来源：Bamboo Works</strong></em></p>
</div><h4><strong>Key Takeaways:</strong></h4>
<div class="lb-trans"><h4><strong>关键要点：</strong></h4>
</div><ul>
<li>The company says it expects to post a net profit ranging from around $6 million to $8 million for its financial year to the end of March</li>
<li>Yidu Tech's AI tools are being adopted into medical workflows, with some client hospitals reported to use them nearly 1,000 times a day</li>
</ul>
<div class="lb-trans"><ul>
<li>公司表示预计截至 3 月底的财年将实现净利润约为 600 万至 800 万美元</li>
<li>医渡科技的人工智能工具正在被纳入医疗工作流程，一些客户医院的使用频率接近每天 1000 次</li>
</ul>
</div><p>For years, medical AI has generated plenty of excitement but has struggled to show it can make money. That situation may be starting to change, as one Chinese provider of healthcare technology prepares to mark an earnings milestone.</p>
<div class="lb-trans"><p>多年来，医疗人工智能引发了大量的兴奋，但一直难以证明其盈利能力。这种情况可能正在发生变化，因为一家中国医疗科技提供商准备迎来盈利里程碑。</p>
</div><p><strong>Yidu Tech Inc.</strong> (2158.HK) <strong>announced</strong> on April 20 it expects to post the first annual profit in its 11-year history, potentially marking an inflection point for the broader AI-powered healthcare sector.</p>
<div class="lb-trans"><p><strong>医渡科技有限公司</strong>（2158.HK）<strong>宣布</strong> 于 4 月 20 日预计将在其 11 年历史中首次实现年度盈利，这可能标志着更广泛的人工智能驱动医疗行业的转折点。</p>
</div><p>The supplier of big data and tech solutions for the medical sector projected a net profit of between 41 million yuan and 56 million yuan ($6 million and $8.2 million) for its financial year to the end of March, rebounding from a loss of around 118 million yuan in the previous year.</p>
<div class="lb-trans"><p>这家为医疗行业提供大数据和技术解决方案的供应商预计截至 3 月底的财年将实现净利润在 4100 万至 5600 万元人民币（600 万至 820 万美元）之间，较去年约 1.18 亿元的亏损有所回升。</p>
</div><p>In explaining the turnaround, the company cited a surge in new orders as it integrates AI into its products, driving higher gross margins, as well as better operating efficiency and economies of scale.</p>
<div class="lb-trans"><p>在解释扭转局面时，公司提到新订单激增，因为它将人工智能整合到其产品中，从而推动了更高的毛利率，以及更好的运营效率和规模经济。</p>
</div><p>It was clear from Yidu Tech's half-year earnings that the firm was heading towards breakeven. Revenues for the six months to end-September rose 8.7% to 358 million yuan, reversing a contraction in the year-earlier period. Gross margin rose to 37.4%.  from 35.6% while operating losses narrowed by 71% to 15.71 million yuan and net losses shrank 72% to 15.76 million yuan.</p>
<div class="lb-trans"><p>从医渡科技的半年财报中可以清楚地看出，该公司正朝着盈亏平衡的方向发展。截止 9 月底的六个月收入增长了 8.7%，达到 3.58 亿元，扭转了去年同期的收缩。毛利率从 35.6% 上升至 37.4%。运营亏损缩小了 71%，降至 1571 万元，净亏损缩小了 72%，降至 1576 万元。</p>
</div><p>Those interim results showed that growth was increasingly being driven by application-based solutions for hospitals and payment systems, rather than pharmaceutical services.</p>
<div class="lb-trans"><p>这些中期结果显示，增长越来越多地由医院的应用解决方案和支付系统驱动，而不是制药服务。</p>
</div><p>Half-year revenue from the company's big data platform and solutions grew 14.6% year on year, while income from the health management segment jumped 30.3%. In contrast, life sciences solutions for pharmaceutical companies slipped 4.4%. In terms of the revenue mix, the big data platform business remains the largest contributor to the top line.</p>
<div class="lb-trans"><p>公司大数据平台和解决方案的半年收入同比增长 14.6%，而健康管理部门的收入跃升 30.3%。相比之下，针对制药公司的生命科学解决方案下降了 4.4%。在收入构成方面，大数据平台业务仍然是收入的最大贡献者。</p>
</div><p>As the AI momentum shifts from large models to real-world deployment, investors are increasingly focused on whether the technology can be embedded into workflows to generate returns. In healthcare, that would mean integrating artificial intelligence into clinical care, research or payment systems.</p>
<div class="lb-trans"><p>随着人工智能的势头从大型模型转向实际部署，投资者越来越关注该技术是否能够嵌入工作流程以产生回报。在医疗保健领域，这意味着将人工智能整合到临床护理、研究或支付系统中。</p>
</div><p>Few Chinese AI healthcare companies have so far crossed the profit threshold. For example, <strong>iFlytek Healthcare</strong> (2506.HK) focuses on primary care and voice interaction scenarios. It has expanded rapidly through standardized tools yet still reported a loss of 64.79 million yuan in 2025. <strong>Airdoc Technology</strong> (2251.HK) concentrates on single-point applications such as retinal image recognition with a relatively clear but limited business model, leaving it with a loss of 24.97 million yuan last year.</p>
<div class="lb-trans"><p>迄今为止，只有少数中国人工智能医疗公司跨越了盈利门槛。例如，<strong>科大讯飞医疗</strong>（2506.HK）专注于初级护理和语音交互场景。它通过标准化工具迅速扩展，但在 2025 年仍报告亏损 6479 万元。<strong>Airdoc 科技</strong>（2251.HK）专注于单点应用，如视网膜图像识别，商业模式相对清晰但有限，去年亏损 2497 万元。</p>
</div><p>Yidu Tech has taken a different path. In its early stages, the company developed medical platforms and disease-specific databases, building a large pool of structured data and a wide base of hospital clients. More recently it has shifted from simply providing information to participating in healthcare decisions through products such as a clinical Copilot and an evidence-based AI agent.</p>
<div class="lb-trans"><p>医渡科技采取了不同的路径。在早期阶段，公司开发了医疗平台和特定疾病数据库，建立了大量结构化数据和广泛的医院客户基础。最近，它已从单纯提供信息转变为通过临床助手和基于证据的人工智能代理参与医疗决策。</p>
</div><p>These tools appear to be finding their way into clinical workflows, according to usage data contained in the half-year earnings report, with some hospitals reported to be accessing them nearly 1,000 times a day. Such high-frequency uptake could be the key to generating stable returns from the business of AI-powered healthcare.</p>
<div class="lb-trans"><p>根据半年财报中的使用数据，这些工具似乎正在逐渐融入临床工作流程，一些医院的访问频率接近每天 1000 次。这种高频率的使用可能是从人工智能驱动的医疗业务中产生稳定回报的关键。</p>
</div><p>Meanwhile, the company has demonstrated scalability in serving more than 10,000 medical institutions and partnering with over 100 top-tier hospitals. However, a correlation between wide take-up and monetary returns has yet to be clearly established.</p>
<div class="lb-trans"><p>与此同时，公司在服务超过 1 万家医疗机构和与 100 多家顶级医院合作方面展示了可扩展性。然而，广泛采用与经济回报之间的相关性尚未明确建立。</p>
</div><h4><strong>Uncertain outlook</strong></h4>
<div class="lb-trans"><h4><strong>前景不确定</strong></h4>
</div><p>Revenue growth remains in the single digits, with no clear sign of acceleration. Based on the outline figures for full year, it is hard to determine how sustainable the profits will be. Moreover, the adoption of healthcare AI is highly dependent on hospital procurement cycles and supportive government policies, affecting the pace and scope of expansion.</p>
<div class="lb-trans"><p>收入增长仍处于个位数，没有明显加速的迹象。根据全年初步数据，很难判断利润的可持续性。此外，医疗人工智能的采用高度依赖于医院采购周期和政府支持政策，影响扩展的速度和范围。</p>
</div><p>The company could still be in a transitional stage in which its business model is taking shape but remains unproven. Yidu Tech's earnings breakthrough shows that AI healthcare can be monetized in specific scenarios, but it may not be sustainable or replicated across the whole sector.</p>
<div class="lb-trans"><p>公司仍可能处于过渡阶段，其商业模式正在形成但尚未得到验证。医渡科技的盈利突破表明，人工智能医疗在特定场景中可以实现货币化，但可能无法在整个行业中持续或复制。</p>
</div><p>Still, the profit projection lifted the company's shares. After the announcement, the stock rose 3.8% to close at HK$6.3, for a year-to-date gain of 18.4%. Yidu Tech is trading at a price-to-sales ratio of about 7.5 times, broadly in line with iFlytek Healthcare at around 8 times and Airdoc Technology at about 6 times. This suggests investors are still basing their valuation on revenue scale and growth potential, rather than profitability.</p>
<div class="lb-trans"><p>尽管如此，利润预测推动了公司股价的上涨。在公告后，股价上涨 3.8%，收于 6.3 港元，年初至今涨幅为 18.4%。医渡科技的市销率约为 7.5 倍，基本与科大讯飞医疗的约 8 倍和 Airdoc 科技的约 6 倍相当。这表明投资者仍然基于收入规模和增长潜力而非盈利能力来评估其价值。</p>
</div><p>If Yidu Tech can stay in the black over the next few quarters and accelerate its revenue growth, the stock may have room to rise. But if profits falter, the valuation may have already peaked out.</p>
<div class="lb-trans"><p>如果医渡科技在接下来的几个季度内能够保持盈利并加速收入增长，股价可能还有上涨空间。但如果利润下滑，估值可能已经达到顶峰。</p>
</div><p><em>To subscribe to Bamboo Works weekly free newsletter, click</em> here</p>
<div class="lb-trans"><p><em>要订阅 Bamboo Works 每周的免费通讯，请点击</em> 这里</p>
</div><p><strong><em>Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.</em></strong></p>
<div class="lb-trans"><p><strong><em>Benzinga 免责声明：本文来自未付的外部贡献者。它不代表 Benzinga 的报道，并且未经过内容或准确性的编辑。</em></strong></p>
</div>

Yidu Tech Swings To Profit Signaling An Inflection Point For AI Healthcare

- Yidu Tech 预计实现首个年度净利润，范围为 600 万至 800 万美元。  
- 医疗 AI 被快速应用于临床工作流程，部分医院每日使用近 1,000 次。  
- 盈利前景仍存不确定性， revenue 增长乏力，受医院采购和政策影响。

医渡科技实现盈利，标志着人工智能医疗保健领域的一个拐点